This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Endo International plc
Drug Names(s): EPI-A0001
Description: A0001, a coenzyme Q molecular analog, has shown biological activity in cell assaysdeveloped by Edison to test the ability of this class of compounds to improve mitochondrial function. In preclinical studies, it increases significantly the amount of energy produced by mitochondria and reduces the amount of oxidative stress around the mitochondria. It is thought that EPI-A0001 accomplishes this by assisting in the transport of electrons across the respiratory chain complexes of the mitochondria so that more ATP is produced and fewer oxidative radicals are formed. Impairment of mitochondrial function is commonly believed to be a significant factor in a number of inheriteddisorders, including Friedreich’s Ataxia, Leber’s Hereditary Optical Neuropathy, Coenzyme Q10 DeficiencySyndrome and MELAS syndrome.
Deal Structure: In July 2007, Penwest entered into a collaboration and licensing agreement with Edison Pharmaceuticals. Under the Edison agreement, Penwest has agreed with Edison tocollaborate on the development of A0001 and up to one additional drug candidate of Edisons, initially for thetreatment of inherited mitochondrial respiratory chain diseases.
During the initial 18 months of the agreement, Edison is obligated to present to Penwest at least one compoundidentified by Edison that satisfies agreed-upon criteria for consideration as a development candidate under thecollaboration, in addition to A0001. Penwest has the option, exercisable upon payment of a one-time fee, to selectany such compound for development.
Under the Edison agreement, Penwest has exclusive, worldwide rights to develop and commercialize A0001and any other compound as to which it has exercised its option, or any replacement compound, for thetreatment of all indications, subject to other terms and conditions in the...See full deal structure in Biomedtracker
Partners: Edison Pharmaceuticals, Inc.
Additional information available to subscribers only: